Cameron Patrice, Lesko Jana, London Marla R
Providence St. Vincent Medical Center.
Clin J Oncol Nurs. 2018 Feb 1;22(1):E18-E22. doi: 10.1188/18.CJON.E18-E22.
BACKGROUND: Patients are increasingly presenting for outpatient breast biopsy while taking medically necessary antithrombotic therapy. Cessation of this medication prior to biopsy increases patients' risk of vascular complications. .
OBJECTIVES: This article evaluates the safety of performing core needle biopsies of the breast in patients without suspending prescription antithrombotic therapy. .
METHODS: In this retrospective chart review study, patients continued prescription antithrombotic therapy prior to and including the day of biopsy. Follow-up telephone assessment, relying on patient self-report, was completed on the same or next business day. The chart review included report of bleeding as a postprocedure complication. .
None of the 42 women who completed core needle biopsy of the breast while on antithrombotic therapy reported postdischarge bleeding, and 2 reported hematoma, supporting the safety of continuing antithrombotic therapy in patients who undergo core needle biopsy of the breast.
越来越多的患者在接受必要的抗血栓治疗时前来进行门诊乳房活检。活检前停用这种药物会增加患者发生血管并发症的风险。
本文评估在不暂停处方抗血栓治疗的情况下对患者进行乳房粗针活检的安全性。
在这项回顾性图表审查研究中，患者在活检当天及之前继续进行处方抗血栓治疗。在同一个或下一个工作日，通过患者自我报告完成随访电话评估。图表审查包括将出血报告为术后并发症。
42名在接受抗血栓治疗期间完成乳房粗针活检的女性中，没有人报告出院后出血，2人报告有血肿，这支持了在接受乳房粗针活检的患者中继续进行抗血栓治疗的安全性。
